Compare Citius Pharmaceuticals Inc (CTXR) vs M&T Bank Corporation (MTB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs M&T Bank Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $18.73M), while M&T Bank Corporation trades at $251.93 (market cap $36.27B). The key difference: M&T Bank Corporation is far larger — about 1936.5× Citius Pharmaceuticals Inc's market cap, and M&T Bank Corporation pays a 2.39% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | MTB | |
|---|---|---|
Market Cap | $18.73M | $36.27B |
Sector | Health | Financials |
52-Week High | $1.82 | $254.04 |
52-Week Low | $0.48 | $178.63 |
Enterprise Value | $14.95M | — |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR is trading at $0.68, up 6.28% today, with a bullish technical signal from moving averages. The company shows strong commercial momentum with LYMPHIR cancer treatment revenue reaching $5.6 million in H1 2026, though it remains unprofitable with a -823% net margin. Analyst consensus is strongly bullish with 83% buy ratings.
The outlook depends on LYMPHIR's commercial success offsetting deep losses. Near-term catalysts include expanded market access and combination therapy data, but high cash burn and execution risks require monitoring. The stock offers speculative growth potential in oncology but carries significant financial risk.
M&T Bank Corporation (MTB) trades at $250.45, up 0.12% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock is supported by strong fundamentals, including a net income margin of 30.85% and a P/E ratio of 13.26, indicating reasonable valuation. Recent Q2 2026 results showed record EPS of $5.35, exceeding expectations, driven by loan growth and net interest income. The consensus price target is $255.92, suggesting modest upside from current levels.
The outlook for MTB remains positive, supported by operational excellence and dividend payments, but risks include macroeconomic sensitivity and competitive pressures in regional banking. Investor sentiment is cautiously optimistic, with analysts largely holding a neutral to buy stance, while institutional ownership trends and cash flow management will be key to sustaining growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →
